Muscle Repair & Anti Inflammatory Research Compounds Canada FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA moves toward easing restrictions on certain peptides BioPharma Dive In 2023, the FDA deemed 19 peptide drugs too unsafe to be dispensed by compounding pharmacies, which mix components of approved drugs to create bespoke medication for people who have trouble taking BPC 157: Experimental Peptide Creates Risk for Athletes